Drug Trial Radar · NCT01290887
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
Last checked: Nov 20, 2026Latest source record: Jun 6, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,052
Actual
Start
Jun 2011
Primary completion
Jan 2015
Study completion Jan 2015
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Feb 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by adverse events, physical examination findings, vital sign measurements, and concomitant medication usage throughout the study (every 4 weeks), clinical laboratory test results, and measurement of antidrug antibodies.
Conditions
- Eosinophilic Asthma
Interventions
ReslizumabDrug
Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Treatment-Emergent Adverse EventsTime frame: Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.
- Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab ValuesTime frame: Weeks 4, 8, 24 and 48
- Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs ValuesTime frame: Week 4 to Week 65
Locations
219 sites in 31 countries. Site status is shown where the registry gives one.
Teva Investigational Site 58
Scottsdale, Arizona
Teva Investigational Site 12
Anaheim, California
Teva Investigational Site 11
Fountain Valley, California
Teva Investigational Site 41
Fresno, California
Teva Investigational Site 59
Long Beach, California
Teva Investigational Site 43
Los Angeles, California
Teva Investigational Site 4
Orange, California
Teva Investigational Site 15
Walnut Creek, California
Teva Investigational Site 2
Colorado Springs, Colorado
Teva Investigational Site 34
Colorado Springs, Colorado
Teva Investigational Site 47
Denver, Colorado
Teva Investigational Site 28
Waterbury, Connecticut
Teva Investigational Site 53
Clearwater, Florida
Teva Investigational Site 24
Largo, Florida
Teva Investigational Site 27
Miami, Florida
Teva Investigational Site 55
Miami, Florida
Teva Investigational Site 5
Miami, Florida
Teva Investigational Site 52
Orlando, Florida
Teva Investigational Site 19
Tallahassee, Florida
Teva Investigational Site 17
Trinity, Florida
Teva Investigational Site 18
Valrico, Florida
Teva Investigational Site 25
Lawrenceville, Georgia
Teva Investigational Site 6
Lilburn, Georgia
Teva Investigational Site 3
Savannah, Georgia
Teva Investigational Site 49
Lexington, Kentucky
Teva Investigational Site 46
Bangor, Maine
Teva Investigational Site 40
St Louis, Missouri
Teva Investigational Site 74
St Louis, Missouri
Teva Investigational Site 64
Boys Town, Nebraska
Teva Investigational Site 8
Omaha, Nebraska
Teva Investigational Site 26
Summit, New Jersey
Teva Investigational Site 30
Winston-Salem, North Carolina
Teva Investigational Site 20
Cincinnati, Ohio
Teva Investigational Site 31
Cincinnati, Ohio
Teva Investigational Site 50
Oklahoma City, Oklahoma
Teva Investigational Site 1
Medford, Oregon
Teva Investigational Site 66
Altoona, Pennsylvania
Teva Investigational Site 73
Lincoln, Rhode Island
Teva Investigational Site 9
Providence, Rhode Island
Teva Investigational Site 21
Charleston, South Carolina
Showing 40 of 219 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.